title: [CDDP-ACR treatment in patients with recurrent ovarian cancer with prior chemotherapy containing CDDP--a preliminary study of a 14-day continuous infusion of CDDP with ACR].
abstract: Six patients with recurrent ovarian cancer who had prior chemotherapy were studied for the clinical efficacy of CDDP-ACR treatment. Five out of the 6 had received CDDP a total doses of 1,320, 780, 750, 475, and 340 mg. CDDP-ACR therapy consisted of continuous infusion of CDDP at a daily dose of 10 mg/m2 over 14 days (total CDDP doses; 140 mg/m2) and of intermittent infusion of ACR (aclarubicin) at a dose of 20 mg/body every other day (total ACR doses: 140 mg). There were one CR and five PR and a response rate up to 100% was noted. Toxicity was manifested in slight nausea or vomiting, but there was no nephrotoxicity. However bone marrow was severe. Thrombocytopenia less than 50,000/mcl in 4 pts (67%) and leukopenia less than 1,000 mcl in 3 pts (50%). The mean filterable platinum exposure measured by area under the concentration-time curve (AUC) was as high as 19.7 +/- 6/0 mg.hr/ml. In conclusion the bone marrow toxicity in this regimen was severe, but the therapeutic efficacy was promising. Further studies on the appropriate infusion time and the minimum effective dose of CDDP are needed.
authors.affiliation: Department of Gynecology, Cancer Institute Hospital, Tokyo.
authors.forename: J T
authors.initials: JT
authors.lastname: Chen
authors.forename: Y
authors.initials: Y
authors.lastname: Hirai
authors.forename: K
authors.initials: K
authors.lastname: Nakayama
authors.forename: Y
authors.initials: Y
authors.lastname: Shimizu
authors.forename: K
authors.initials: K
authors.lastname: Yokosuka
authors.forename: H
authors.initials: H
authors.lastname: Teshima
authors.forename: T
authors.initials: T
authors.lastname: Hamada
authors.forename: I
authors.initials: I
authors.lastname: Fujimoto
authors.forename: K
authors.initials: K
authors.lastname: Yamauchi
authors.forename: K
authors.initials: K
authors.lastname: Hasumi
mesh_terms: D000008:Abdominal Neoplasms / Q000188:drug therapy / Q000556:secondary; D015250:Aclarubicin / Q000008:administration & dosage / Q000009:adverse effects; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003536:Cystadenocarcinoma / Q000188:drug therapy* / Q000556:secondary; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007970:Leukopenia / Q000139:chemically induced; D008207:Lymphatic Metastasis; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D010984:Platinum / Q000097:blood / Q000493:pharmacokinetics; D012008:Recurrence; D012074:Remission Induction; D013921:Thrombocytopenia / Q000139:chemically induced
chemical_list: D010984:Platinum; D015250:Aclarubicin; D002945:Cisplatin